History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology

Publisher： Karger

E-ISSN： 1421-9670|45|3|235-247

ISSN： 0250-8095

Source： American Journal of Nephrology, Vol.45, Iss.3, 2017-02, pp. : 235-247

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia

By  

Cardiorenal Medicine, Vol. 7, Iss. 3, 2017-04 ,pp. : 188-197

Karger

Access to resources Recommend Favorite

Healthcare Resource Utilization for Anemia Management: Current Practice with Erythropoiesis-Stimulating Agents and the Impact of Converting to Once-Monthly C.E.R.A.

By  

Blood Purification, Vol. 26, Iss. 6, 2008-11 ,pp. : 537-546

Karger

Access to resources Recommend Favorite

Low-Dose Treatment with Erythropoiesis-Stimulating Agents and Cardiovascular Geometry in Chronic Kidney Disease: Is Darbepoetin-α More Effective than Expected?

By  

Cardiorenal Medicine, Vol. 2, Iss. 1, 2011-12 ,pp. : 18-25

Karger

Access to resources Recommend Favorite

Pre-Emptive Replacement of Water Treatment Components Improves Responsiveness to Erythropoiesis-Stimulating Agents in Maintenance Haemodialysis Patients: A Quality Improvement Report

By  

Blood Purification, Vol. 36, Iss. 3-4, 2013-12 ,pp. : 265-273

Karger

Access to resources Recommend Favorite

Dosing of Erythropoiesis-Stimulating Agents Can Be Reduced by a New Administration Regimen

By  

Nephron Extra, Vol. 1, Iss. 1, 2011-08 ,pp. : 45-54

Karger

Access to resources Recommend Favorite